Vivodyne, a Philadephia, PA-based biotech company, raised $38M in Seed funding.
The round was led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.
The company intends to use the funds to advance its discovery pipeline and clinically predictive AI stack, which identifies novel therapeutic targets and predicts patient responses to new drugs by testing directly on lab-grown human organ tissues.
Founded by Andrei Georgescu and Dan Huh, Vivodyne is a biotechnology company that accelerates the development of medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. Robots are used to grow and experiment on lab-grown human organs at massive scale, creating datasets to empower predictive AI platform technology. The company’s platform can cultivate, dose, and analyze more than 10,000 individual human tissues at a time using robotic automation, allowing the production of vast human datasets that will empower human-trained AI for drug discovery.
Vivodyne has bioengineered over 20 types of human organ tissues that mimic native human physiology and function to accurately capture the effects of new therapies and predict patient outcomes at the cellular, tissue, organ, and systemic scale. The company currently has collaborations with the majority of the top 10 large pharma companies.
FinSMEs
22/11/2023